Brief: Corbus Pharmaceuticals Presents The First Pre-Clinical Characterization Of Its Next Generation Nectin-4 ADC CRB-701

Corbus Pharmaceuticals Holdings

16/10/2023 14:03

Oct 16 (Reuters) - Corbus Pharmaceuticals Holdings Inc
 CRBP.O :
    * CORBUS PHARMACEUTICALS PRESENTS THE FIRST PRE-CLINICAL
CHARACTERIZATION OF ITS NEXT GENERATION NECTIN-4 ADC CRB-701
    * CORBUS PHARMACEUTICALS HOLDINGS INC - CRB-701 DEMONSTRATES
A
DIFFERENTIATED NONCLINICAL PROFILE RELATIVE TO ENFORTUMAB
VEDOTIN
    * CORBUS PHARMACEUTICALS HOLDINGS INC - EARLY DOSE
ESCALATION
CLINICAL DATA SUPPORTS DIFFERENTIATING FEATURES ESTABLISHED
PRE-CLINICALLY
    * CORBUS PHARMACEUTICALS HOLDINGS INC - ON SCHEDULE TO
INITIATE
ITS US STUDY IN Q1-2024

Source text for Eikon:  ID:nGNXch6ZDL 
Further company coverage:  CRBP.O 

 ((Reuters.Briefs@thomsonreuters.com;))